Select a Region North America


Mike Kurland

Michael Kurland

Vice President, Revenue Management & Compliance Solutions



With more than 2 decades of experience in the pharmaceutical and biotech industries, Michael helps clients navigate the complex public and private payer marketplace. He has a proven reputation for helping manufacturers balance their market share goals and commercial rebate strategies with government pricing impacts and compliance.

Throughout his career, Michael has developed, implemented, and managed business strategies and technical solutions for government pricing, market access, rebate and chargeback processing and data analytics. And, in this context, it makes perfect sense that his areas of expertise include government pricing compliance, public payer strategy development, business analysis, project management, process and system reviews, selections and implementations, and cross-functional team management. Previously, Michael served as director at several life science consulting firms, as well as associate director of government regulated systems at Auxilium Pharmaceuticals, Inc. He holds a bachelor of science degree from Penn State University.

Events with Michael Kurland

Articles by Michael Kurland

Understanding the Inflation Reduction Act: Inflation Rebates

Prescription drug manufacturers routinely implement price increases for a variety of reasons that support their business. With the passage of the Inflation Reduction Act late in 2022, Congress added a twist to these price increases. One provision of the Act, also known as the IRA, implements rebates from pharmaceutical companies to Medicare for price increases that outpace inflation. The Centers for Medicare and Medicaid Services (CMS), the federal agency that oversees Medicare, recently issued guidance for manufacturers to operationalize the statute. Common Elements The IRA mandates that pharmaceutical manufacturers that sell their products prescribed to Medicare Part B and Part D beneficiaries will be subject to these inflation rebates. For […]

The State of National Healthcare Policy and Pricing Webinar 2023

2023 is shaping up to be an interesting year for Pharma/Biotech companies and their commercial and government pricing strategies and contracts. There are multiple policies and rules being discussed, already proposed, under review, in litigation, and that need to be implemented this year.  “The State of National Healthcare Policy and Pricing Webinar 2023” hosted by Informa Connect kicked of 2023 with a discussion reviewing the evolving healthcare policy and GP regulations and how they will affect you and your company.     Key topics include:   Impacts from the Inflation Reduction Act   Updates on Territories and Puerto Rico   Changes to Federal and State Drug Pricing, Reimbursement and Transparency   340B   Next Gen GPO’s including […]

Ask the Attorneys: What Keeps Them Up at Night

EVERSANA’s Mike Kurland, Vice President, Revenue Management and Compliance, joined a panel of industry experts to present, “Ask the Attorneys: What Keeps Them Up at Night?” at Informa Connect’s Medical Drug Rebate Program Summit. Session Summary The complex pharmaceuticals regulatory framework is ever-changing at both the federal and state levels. This volatility is caused by the government entering the market in new ways and the constant possibility of the unknown and legislative change. For these reasons and many more, internal and external experts are crucial to help manufacturers be prepared and develop ways to challenge statutes. For example, at the federal level, the Inflation Reduction Act under Medicare potentially coming […]

Operational Concerns for Key Enacted and Proposed Changes Under Medicare and Medicaid

EVERSANA’s Mike Kurland, Vice President, Revenue Management & Compliance, delivered a presentation on Operational Concerns for Key Enacted and Proposed Changes Under Medicare and Medicaid at Informa Connect’s Medicaid & Government Pricing Congress. Mike discussed the importance of balancing Federal and state regulations organizationally and reported on recent activity.   Balancing Federal and State Regulations Across All Operations   Groups responsible for Government Affairs must routinely assess proposed Federal and state laws and regulations to identify which are most likely to be enacted. By focusing on these laws and regulations, manufacturers can measure organizational impacts for commercial strategy, government pricing, finances, systems, data and processes. This exercise will also allow for ample […]

Global Pharma Pricing Regulations
Webinar: Medicaid & Government Pricing Congress

In this Medicaid & Government Pricing Congress panel, EVERSANA’s Mike Kurland, Vice President, Revenue Management and Compliance Solutions, discusses upcoming regulatory changes impacting government pricing and how to manage challenging reporting issues with calculation. How to Manage Challenging Reporting Issues with Calculation​ This panel covers: Operational components Legal components Aligning with internal/external teams on handling returns Partial fill vials How do you interpret regulation when figuring out return value in excess of cost? Meet with our revenue management and government pricing experts today.

Webinar: Drug Pricing and Reporting Regulatory Updates Part 2

In Part 2 of our Drug Pricing and Reporting Regulatory Updates webinar, EVERSANA revenue experts  take a look at the Final Rule, which was released by the Centers for Medicare and Medicaid Services in December 2020. Legislative actions related to the rule will go into effect through 2023. This webinar specifically looks at how the following factors will affect pricing for manufacturers: Coupons, Vouchers, Accumulators Line Extensions/Oral Solid Dosages Average Manufacturer Price for Authorized Generics Supplemental Rebates to Medicaid MCOs Watch Part 1 of the Drug Pricing and Reporting Regulatory Updates webinar here for the latest Biden administration updates.   For an in-depth look at current drug pricing and drug price reporting regulatory updates, download the white paper. 

Webinar: Drug Pricing and Reporting Regulatory Updates Part 1

Pharmaceutical companies in the U.S. are navigating President Biden’s new administration and legislative changes that are affecting pricing and regulatory actions.   One of these changes includes the regulatory freeze ordered for actions made in the final two months of the Trump administration, which has paused Medicare Part B and Medicare Part D legislation as well.  In part one of our drug pricing and reporting regulatory updates webinar, EVERSANA’s Michael Kurland and Brian Abraham discuss what pharma companies need to know about the regulatory freeze and what legislative lag means for pricing and regulation. Specifically, Part 1 looks at the following:   Updates on Actions by the Biden Administration  Medicare Part B: Most Favored Nation  Medicare Part D: Rebate Safe […]

Drug Pricing And Drug Price Reporting Regulatory Update

As the new president and Congress begin their terms, EVERSANA would like to provide an update on recent legislative and regulatory actions that affect drug pricing and price reporting. The Centers for Medicare and Medicaid Services (CMS) issued this interim final rule on November 20, 2020 (85 Fed Reg 76180-76259), requiring a revised calculation of payments for the top 50 drugs by historic spending under Medicare Part B. The new payment level, to be phased in over four years, is based on the lowest price paid by a member country of the Organization of Economic Cooperation and Development (OECD) with at least 60% of the per-capita gross domestic product (GDP) of […]

Challenges and Best Practices in Managing Value Based Contracts

Manufacturers face a variety of hurdles when negotiating value based contracts: from data access and standardization, deal structure variation, payment variability and scheduling, to changing laws and regulations. And, as the industry shifts to value-driven healthcare, the demand for innovative product commercialization and pricing models grows. In this webinar EVERSANA experts Robert Blank and Mike Kurland provide insight into this growing need by reviewing the obstacles associated with operationalizing value-based contracts, sharing best practices, and presenting a holistic “ideal state.” Watch the Webinar: Challenges and Best Practices in Managing Value Based Contracts

Interested in scheduling a meeting or speaking event?